Suppr超能文献

用于结直肠癌筛查的粪便免疫化学检测结果不理想:患病率、原因及后续检测

Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing.

作者信息

Liu Po-Hong, Nair Rasmi G, Skinner Celette Sugg, Murphy Caitlin C, Kim Eric J, Ortiz Cynthia, Wang Lei, Hu Ellen, Lykken Jacquelyn M, Levin Theodore R, Green Beverly B, Hahn Erin E, Santini Noel, Halm Ethan A

机构信息

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.

Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas.

出版信息

Cancer Epidemiol Biomarkers Prev. 2024 Feb 6;33(2):215-223. doi: 10.1158/1055-9965.EPI-23-0507.

Abstract

BACKGROUND

Fecal immunochemical test (FIT) is an effective colorectal cancer screening modality. Little is known about prevalence, reasons, and testing after unsatisfactory FIT, or a FIT that cannot be processed by the laboratory due to inadequate stool specimen or incomplete labeling.

METHODS

Our retrospective cohort study examined unsatisfactory FIT among average-risk individuals aged 50-74 years in a large, integrated, safety-net health system who completed an index FIT from 2010 to 2019. We determined prevalence of unsatisfactory FIT and categorized reasons hierarchically. We used multivariable logistic regression models to identify factors associated with: (i) unsatisfactory FIT; and (ii) subsequent testing within 15 months of the unsatisfactory FIT.

RESULTS

Of 56,980 individuals completing an index FIT, 10.2% had an unsatisfactory FIT. Reasons included inadequate specimen (51%), incomplete labeling (27%), old specimen (13%), and broken/leaking container (8%). Unsatisfactory FIT was associated with being male [OR, 1.10; confidence interval (CI), 1.03-1.16], Black (OR, 1.46; CI, 1.33-1.61), Spanish speaking (OR, 1.12; CI, 1.01-1.24), on Medicaid (OR, 1.42; CI, 1.28-1.58), and received FIT by mail (OR, 2.66; CI, 2.35-3.01). Among those with an unsatisfactory FIT, fewer than half (41%) completed a subsequent test within 15 months (median, 4.4 months). Adults aged 50-54 years (OR, 1.16; CI, 1.01-1.39) and those who received FIT by mail (OR, 1.92; CI, 1.49-2.09) were more likely to complete a subsequent test.

CONCLUSIONS

One in ten returned a FIT that could not be processed, mostly due to patient-related reasons. Fewer than half completed a subsequent test after unsatisfactory FIT.

IMPACT

Screening programs should address these breakdowns such as specimen collection and labeling to improve real-world effectiveness. See related In the Spotlight, p. 183.

摘要

背景

粪便免疫化学检测(FIT)是一种有效的结直肠癌筛查方式。对于FIT结果不满意,或者由于粪便标本不足或标签不完整而导致实验室无法处理的FIT的患病率、原因及后续检测情况,人们了解甚少。

方法

我们的回顾性队列研究调查了在一个大型综合安全网卫生系统中年龄在50 - 74岁的平均风险个体中FIT结果不满意的情况,这些个体在2010年至2019年期间完成了首次FIT检测。我们确定了FIT结果不满意的患病率,并对原因进行了分层分类。我们使用多变量逻辑回归模型来确定与以下因素相关的因素:(i)FIT结果不满意;(ii)在FIT结果不满意后的15个月内进行后续检测。

结果

在56,980名完成首次FIT检测的个体中,10.2%的个体FIT结果不满意。原因包括标本不足(51%)、标签不完整(27%)、标本陈旧(13%)以及容器破损/泄漏(8%)。FIT结果不满意与男性[比值比(OR),1.10;置信区间(CI),1.03 - 1.16]、黑人(OR,1.46;CI,1.33 - 1.61)、说西班牙语(OR,1.12;CI,1.01 - 1.24)、参加医疗补助计划(OR,1.42;CI,1.28 - 1.58)以及通过邮寄方式接受FIT检测(OR,2.66;CI,2.35 - 3.01)有关。在FIT结果不满意的个体中,不到一半(41%)在15个月内(中位数为4.4个月)完成了后续检测。50 - 54岁的成年人(OR,1.16;CI,1.01 - 1.39)以及通过邮寄方式接受FIT检测的人(OR,1.92;CI,1.49 - 2.09)更有可能完成后续检测。

结论

十分之一的人返回的FIT检测无法处理,主要是由于与患者相关的原因。FIT结果不满意后,不到一半的人完成了后续检测。

影响

筛查项目应解决这些问题,如标本采集和标签问题,以提高实际效果。见相关“聚焦”,第183页。

相似文献

1
Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing.
Cancer Epidemiol Biomarkers Prev. 2024 Feb 6;33(2):215-223. doi: 10.1158/1055-9965.EPI-23-0507.
2
Disparities in Colorectal Cancer Screening Practices in a Midwest Urban Safety-Net Healthcare System.
Dig Dis Sci. 2021 Aug;66(8):2585-2594. doi: 10.1007/s10620-020-06545-3. Epub 2020 Aug 20.
3
Equitable Implementation of Mailed Stool Test-Based Colorectal Cancer Screening and Patient Navigation in a Safety Net Health System.
J Gen Intern Med. 2023 May;38(7):1631-1637. doi: 10.1007/s11606-022-07952-0. Epub 2022 Dec 1.
4
Predictors of Colorectal Cancer Screening Modality Among Newly Age-Eligible Medicaid Enrollees.
Am J Prev Med. 2021 Jan;60(1):72-79. doi: 10.1016/j.amepre.2020.08.003. Epub 2020 Nov 19.
7
Reasons for Lack of Diagnostic Colonoscopy After Positive Result on Fecal Immunochemical Test in a Safety-Net Health System.
Am J Med. 2017 Jan;130(1):93.e1-93.e7. doi: 10.1016/j.amjmed.2016.07.028. Epub 2016 Aug 31.
8
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5.
9

引用本文的文献

1
Comparative Performance of Common Fecal Immunochemical Tests : A Cross-Sectional Study.
Ann Intern Med. 2024 Oct;177(10):1350-1360. doi: 10.7326/M24-0080. Epub 2024 Sep 3.

本文引用的文献

1
Colorectal cancer statistics, 2023.
CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1.
2
Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic.
J Clin Oncol. 2023 Sep 20;41(27):4352-4359. doi: 10.1200/JCO.22.02170. Epub 2023 Feb 23.
3
Stool-Based Tests Mitigate Impacts of COVID-19 on Colorectal Cancer Screening.
Clin Gastroenterol Hepatol. 2023 Jun;21(6):1667-1669.e2. doi: 10.1016/j.cgh.2022.12.014. Epub 2022 Dec 23.
5
Colorectal Cancer Screening and Yield in a Mailed Outreach Program in a Safety-Net Healthcare System.
Dig Dis Sci. 2022 Sep;67(9):4403-4409. doi: 10.1007/s10620-021-07313-7. Epub 2021 Nov 20.
8
Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing.
Clin Gastroenterol Hepatol. 2022 Jan;20(1):145-152. doi: 10.1016/j.cgh.2020.09.042. Epub 2020 Sep 30.
9
Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study.
Therap Adv Gastroenterol. 2020 Sep 9;13:1756284820945388. doi: 10.1177/1756284820945388. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验